RF1NS142103

MODEL-PAIN MODELING DIVERSE EXPERIENCES AND LONGITUDINAL TRAJECTORIES OF PAIN - EMERGENCY DEPARTMENTS (EDS) PROVIDE ~140 MILLION ENCOUNTERS ANNUALLY FOR ALL POPULATIONS (I.E., VARYING DEMOGRAPHICS, INJURIES, COMORBIDITIES) AND SERVE AS A PRIMARY SAFETY NET IN U.S. HEALTHCARE INFRASTRUCTURE FOR INDIVIDUALS OFTEN NOT ENCOUNTERED ELSEWHERE. MOREOVER, OVER 80% OF THESE PATIENTS ARE EXPERIENCING PAIN WITH VARIABLE CAUSES, PERCEPTIONS, AND ENVIRONMENTAL INFLUENCES CHALLENGING OUR UNDERSTANDING TO OPTIMIZE DIAGNOSIS, PROGNOSTICATION, AND TREATMENT. THIS PROPOSAL SEEKS TO LEVERAGE THE ED SETTING TO COMPREHENSIVELY CHARACTERIZE THE FULL RANGE OF INTERINDIVIDUAL DIFFERENCES IN ACUTE PAIN PHENOTYPES, OPTIMAL TREATMENT, AND TRAJECTORIES OF PAIN WITHIN A BIOPSYCHOSOCIAL AND HEALTH SERVICES FRAMEWORK. WE AIM TO: 1) CHARACTERIZE CLINICALLY INFORMED PAIN PHENOTYPES WITH A DATA-DRIVEN MODELING APPROACH, 2) IDENTIFY OPTIMAL PAIN TREATMENT STRATEGIES USING INDIVIDUALIZED TREATMENT REGIMEN (ITR) ESTIMATION METHOD, AND 3) DEVELOP PREDICTIVE MODELS OF PAIN TRAJECTORIES AND PREDICT TRANSITION FROM ACUTE TO CHRONIC PAIN. WE WILL COLLECT THE NECESSARY DATA FOR ROBUST AND COMPREHENSIVE DATA-DRIVEN MODELING IN A PROSPECTIVE OBSERVATIONAL STUDY OF (N=2,400) ED PATIENTS SEEKING CARE FOR ACUTE PAIN. IN ADDITION TO NIH HEAL CORE DOMAINS, WE WILL COLLECT SELF-REPORTED DATA, HEALTH RECORDS, DIGITAL PHYSIOLOGIC MARKERS, AND BIOLOGIC SAMPLES TO MEASURE: (I) AHRQ SOCIAL DETERMINANTS OF HEALTH, (II) CHARACTER, SEVERITY, TIMING OF PAIN, (III) PERCEPTIONS, RESILIENCY, AND BELIEFS, (IV) CO-MORBIDITIES (MEDICAL AND MENTAL HEALTH), (V) PHYSICAL FUNCTION AND SLEEP INTERRUPTIONS, (VI) DIGITAL PHYSIOLOGIC DATA, (VII) MEASURES OF PAIN SENSITIVITY (E.G. VON FREY, THERMAL THRESHOLDS), (VIII) HEALTHCARE UTILIZATION, (IX) TREATMENT ACCESS/EFFECTIVENESS, AND (X) GENOME-WIDE SINGLE NUCLEOTIDE POLYMORPHISMS. OUR COMPREHENSIVE MODELING APPROACH WILL COMBINE ADVANCED AND CUTTING-EDGE METHODS, INFORMED BY AN EXPERT PANEL INCLUDING PERSONS WITH LIVED EXPERIENCE OF CHRONIC PAIN, COMMUNITY STAKEHOLDERS, AND CLINICIANS ALLOWING THE DEVELOPMENT OF CLINICALLY INTERPRETABLE PREDICTIVE MODELS. THIS INNOVATIVE AND HIGH-IMPACT INVESTIGATION WILL PROVIDE THE MISSING LINK IN OUR UNDERSTANDING OF PAIN BY EMBRACING THE REQUIRED BREADTH AND COMPLEXITY. OUR REMARKABLY INTERDISCIPLINARY TEAM IS WELL-POSITIONED FOR THIS SIGNIFICANT CHALLENGE. WE WILL CAPITALIZE ON (I) ED CARE FOR ALL TYPES OF PAIN OCCURRING IN PERSONS WITH COMORBIDITIES AND (II) OUR PROVEN CAPACITY FOR A LONGITUDINAL STUDY OF OFTEN CHALLENGING POPULATIONS IN EPISODIC CARE ENVIRONMENTS WITHOUT ONGOING PROVIDER RELATIONSHIPS. OUR INCLUSION OF PSYCHOSOCIAL, COGNITIVE, BIOLOGIC, AND HEALTH SERVICES MEASUREMENT IS AN ENORMOUS AND NECESSARY ADVANCE. THE QUINTESSENTIAL CONTRIBUTION OF THIS RESEARCH WILL BE MODELS APPROPRIATE TO THE CHALLENGE OF PAIN HETEROGENEITY, HEALTH DISPARITIES, AND PAIN ITSELF. WITHOUT THIS FOUNDATION, WE CANNOT HOPE TO IDENTIFY INTERVENTION TARGETS AND DEVELOP NOVEL INTERVENTIONS SUFFICIENT TO FUNDAMENTALLY TRANSFORM CURRENT PATTERNS IN PAIN-RELATED HEALTH OUTCOMES AND DISPARITIES.

Ohio State University

(1) TO SUPPORT EXTRAMURAL RESEARCH FUNDED BY THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) INCLUDING: BASIC RESEARCH THAT EXPLORES THE FUNDAMENTAL STRUCTURE AND FUNCTION OF THE BRAIN AND THE NERVOUS SYSTEM, RESEARCH TO UNDERSTAND THE CAUSES AND ORIGINS OF PATHOLOGICAL CONDITIONS OF THE NERVOUS SYSTEM WITH THE GOAL OF PREVENTING THESE DISORDERS, RESEARCH ON THE NATURAL COURSE OF NEUROLOGICAL DISORDERS, IMPROVED METHODS OF DISEASE PREVENTION, NEW METHODS OF DIAGNOSIS AND TREATMENT, DRUG DEVELOPMENT, DEVELOPMENT OF NEURAL DEVICES, CLINICAL TRIALS, AND RESEARCH TRAINING IN BASIC, TRANSLATIONAL AND CLINICAL NEUROSCIENCE. THE INSTITUTE IS THE LARGEST FUNDER OF BASIC NEUROSCIENCE IN THE US AND SUPPORTS RESEARCH ON TOPICS INCLUDING BUT NOT LIMITED TO: DEVELOPMENT OF THE NERVOUS SYSTEM, INCLUDING NEUROGENESIS AND PROGENITOR CELL BIOLOGY, SIGNAL TRANSDUCTION IN DEVELOPMENT AND PLASTICITY, AND PROGRAMMED CELL DEATH, SYNAPSE FORMATION, FUNCTION, AND PLASTICITY, LEARNING AND MEMORY, CHANNELS, TRANSPORTERS, AND PUMPS, CIRCUIT FORMATION AND MODULATION, BEHAVIORAL AND COGNITIVE NEUROSCIENCE, SENSORIMOTOR LEARNING, INTEGRATION AND EXECUTIVE FUNCTION, NEUROENDOCRINE SYSTEMS, SLEEP AND CIRCADIAN RHYTHMS, AND SENSORY AND MOTOR SYSTEMS. IN ADDITION, THE INSTITUTE SUPPORTS BASIC, TRANSLATIONAL AND CLINICAL STUDIES ON A NUMBER OF DISORDERS OF THE NERVOUS SYSTEM INCLUDING (BUT NOT LIMITED TO): STROKE, TRAUMATIC INJURY TO THE BRAIN, SPINAL CORD AND PERIPHERAL NERVOUS SYSTEM, NEURODEGENERATIVE DISORDERS, MOVEMENT DISORDERS, BRAIN TUMORS, CONVULSIVE DISORDERS, INFECTIOUS DISORDERS OF THE BRAIN AND NERVOUS SYSTEM, IMMUNE DISORDERS OF THE BRAIN AND NERVOUS SYSTEM, INCLUDING MULTIPLE SCLEROSIS, DISORDERS RELATED TO SLEEP, AND PAIN. PROGRAMMATIC AREAS, WHICH ARE PRIMARILY SUPPORTED BY THE DIVISION OF NEUROSCIENCE, ARE ALSO SUPPORTED BY THE DIVISION OF EXTRAMURAL ACTIVITIES, THE DIVISION OF TRANSLATIONAL RESEARCH, THE DIVISION OF CLINICAL RESEARCH, THE OFFICE OF TRAINING AND WORKFORCE DEVELOPMENT, THE OFFICE OF PROGRAMS TO ENHANCE NEUROSCIENCE WORKFORCE DEVELOPMENT, AND THE OFFICE OF INTERNATIONAL ACTIVITIES. (2) TO EXPAND AND IMPROVE THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. TO UTILIZE THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM, TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute of Neurological Disorders and Stroke (NNDS) [HHS - NIH]

Columbus, Ohio 432012320 United States

Single Zip Code

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional) (RFA-NS-25-020)